"Further positive synergies can be exploited in the pharmaceuticals, patents and cosmetics sectors"

A leading German IP and pharma-law boutique since 1959, Preu Bohlig has offices in Munich, Düsseldorf, Berlin and Hamburg, as well as a branch in Paris. In 2021, Preu Bohlig upgraded its pharma law capabilities under the leadership of Peter von Czettritz, head of the life sciences practice group.

Posted lundi, août 22 2022
"Further positive synergies can be exploited in the pharmaceuticals, patents and cosmetics sectors"

Preu Bohlig x Leaders League

Leaders League. You advise and represent clients in pharmaceutical sector, for German and European law?

Peter von Czettritz. In pharmaceutical law, our expertise covers the clinical and technical development (including GCP and GMP) and subsequent approval of medicinal products in the German and European marketing authorisation systems, with a focus in the area of orphan drugs, legal issues related to the Paediatric regulation, and pharmacovigilance as well as product liability issues.

Our services encompass pharmaceutical contract law, in particular clinical trials and observational studies, distribution schemes, such as co-marketing and co-promotion contracts, regulatory exclusivity rights (regulatory data protection, orphan market exclusivity and the paediatric extension of exclusivity rights), and third-party opposition proceedings.


How has Preu Bohlig grown in recent years?

In 2021, Preu Bohlig was able to further strengthen its advisory expertise in the area of pharma competition and patent law through continuous cross-location cooperation.

The pharma department gained another partner in the Munich office, Alex Meier, at the beginning of 2020. In 2021, Preu Bohlig was able to extend the cross-location cooperation between the Munich and Hamburg offices, which are led by Daniel Hoppe. With the arrival of Dr. Heidenreich in January 2021, further positive synergies can be exploited in the pharmaceuticals, patents and cosmetics sectors. The Munich pharma boutique now houses two equity partners, two councillors and two associates.


What are some of your firm’s recent highlights?

They concern some proceedings of fundamental importance before the ECJ and the Federal Administrative Court, including advising a vaccine manufacturer on the authorisation and distribution of its Covid-19 vaccine in Europe, questions on the new European Veterinary Medicinal Products Regulation, numerous issues related to medical devices under the Medical Devise Regulation (MDR), which now applies accross Europe, and in competition law, there was the new Act against Unfair Competition (UWG), as well as numerous current questions in the areas of food supplements and cosmetics, on top of delimitation questions and health claims.

We also won a case for a medical-devices app

Our success for Fresenius Medical Care at the Federal Court of Justice in a trade-secrets case, centering on the manufacturing process of dialysis technology was driven by Daniel Hoppe and his team of complex procedures experts.

How important are training sessions to the success of your firm?

The young partners take pride in investing in the training of associates - a mutually beneficial strategy which helps the firm cope with increased volumes of work. Given the trend in the industry towards mixed units, pure patent-law firms increasingly call upon the services of PBP when their regular clients, especially German SMEs, need legal background advice or representation. Clients praise our "excellent advice and quick availability".